VALGANCICLOVIR HYDROCHLORIDE (valganciclovir) by Hetero is dna polymerase inhibitors [moa]. Approved for cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see ], cmv disease in kidney, heart and 3 more indications. First approved in 2023.
Drug data last refreshed 19h ago
DNA Polymerase Inhibitors
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
Worked on VALGANCICLOVIR HYDROCHLORIDE at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients